Bawat’s Guidance on 2025 EBITDA

Bawat revised its 2025 full-year EBITDA guidance down to below SEK -11M (previously SEK -9 to -6M), attributing the deterioration to late postponement of orders, while noting the period June–year-end 2025 was almost EBITDA break-even. The company reports a gross profit margin above the 43% reported in H1 2025 and an overall EBITDA improvement of more than 100% versus FY 2024, and says a solid backlog supports a positive EBITDA outlook for 2026. Bawat will publish the full unaudited 2025 financial report on 25 February 2026.

Analysis

Market structure: Bawat’s cut to “below SEK -11M” from SEK -9– -6M increases near-term cash-burn visibility but confirms improving unit economics (gross margin >43% and >100% EBITDA improvement YoY). Immediate winners are Bawat’s BaaS buyers and ports adopting mobile BWMS (lower CAPEX/OPEX); losers are legacy chemical/UV BWMS vendors facing pricing pressure and retrofit complexity. A healthy 2026 backlog implies demand > supply frictions for retrofit slots, supporting pricing power for early movers if backlog converts into revenue over 12–18 months.

Risk assessment: Tail risks include further order postponements, USCG/IMO regulatory changes, or a field reliability issue with pasteurization leading to warranty claims — any of which could blow the path to 2026 EBITDA-positive. Short-term (days–weeks) risk centers on the Feb 25, 2026 report and guidance supplement; medium (3–12 months) is conversion of backlog; long-term (1–3 years) hinges on industry adoption and ship retrofit CAPEX cycles. Hidden dependencies: reliance on shipboard waste-heat availability and port infrastructure for BaaS; both can bottleneck roll-out.

Trade implications: Tactical trade — small, staged long in Bawat (see decisions) sized to absorb binary Feb 25 news with a hard 25% stop; use short-dated call spreads into Feb/Mar 2026 to play guidance upside and limit premium. Relative-value: overweight established marine-equipment names with BWTS exposure (e.g., ALFA.ST Alfa Laval, WRT1V.HE Wärtsilä) vs underweight pure-play chemical/UV providers (e.g., AQUA US Evoqua) to capture secular retrofit demand with lower execution risk.

Contrarian angle: The market may over-penalize a SEK ~3–5M downward swing versus the company’s message of “positive EBITDA 2026” — downside volatility could create a buying window if Feb 25 confirms backlog conversion. Historical parallels: small cleantech marine suppliers that solved integration (waste-heat) attracted strategic buyers and re-rated 2x–4x on credible scale-up. Unintended consequence: rapid order fill without service capacity could force margin dilution; monitor installed-base service margins as an early signal of durable economics.

Key Decisions for Investors

• Establish a staged 1–2% long equity position in Bawat (Nasdaq First North Growth: BAWAT) between now and Feb 24, 2026; tranche 50% now, 50% ahead of the Feb 25 report, with a 25% stop-loss and a 50% take-profit target within 6–12 months if 2026 positive EBITDA guidance is confirmed.
• Buy a defined-risk call spread on Bawat into the Feb/Mar 2026 window (e.g., buy 3–6 month ATM call, sell 30–40% OTM call) to capture upside from the Feb 25 results while limiting premium, sizing to 0.25–0.5% portfolio risk.
• Overweight established marine-equipment names with BWTS exposure: establish a 2–3% long in Alfa Laval (ALFA.ST) and add 1–2% in Wärtsilä (WRT1V.HE) to capture retrofit demand; hedge by shorting 0.5–1% of Evoqua (NYSE: AQUA) for relative-value exposure to incumbents likely to lose share.
• Predefine sell/trim triggers: if Feb 25 report shows full-year EBITDA worse than SEK -15M, reduce Bawat exposure to zero; if backlog conversion guidance confirms >50% conversion to 2026 revenue, add another 1% to Bawat and roll call spreads to 9–12 months.